|
|||||
|
|
Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer |
|
| Authors: | C. Y. Lu P. Srasuebkul A. K. Drew R. L. Ward S.‐A. Pearson |
| Affiliation: | 1. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, , Boston, Massachusetts, USA;2. Adult Cancer Program, Prince of Wales Clinical School and Lowy Cancer Research Centre, Faculty of Medicine, University of New South Wales, , Sydney, New South Wales, Australia |
| Abstract: | |
| Keywords: | breast cancer trastuzumab cardiotoxicity drug safety data linkage |